{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:16:39Z","timestamp":1792678599755,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.intimp.2020.106748","type":"journal-article","created":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T11:52:05Z","timestamp":1594036325000},"page":"106748","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["Efficacy of baricitinib in treating rheumatoid arthritis: Modulatory effects on fibrotic and inflammatory biomarkers in a real-life setting"],"prefix":"10.1016","volume":"86","author":[{"given":"Miriana","family":"d'Alessandro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice","family":"Perillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Metella Refini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bergantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bellisai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Selvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Cameli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Manganelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Conticini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piersante","family":"Sestini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Frediani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Bargagli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2020.106748_b9005","doi-asserted-by":"crossref","DOI":"10.1007\/s10067-020-04996-7","article-title":"Effects of rituximab therapy on B cell differentiation and depletion","author":"Bergantini","year":"2020","journal-title":"Clin. Rheumatol."},{"issue":"6","key":"10.1016\/j.intimp.2020.106748_b0005","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.intimp.2020.106748_b0010","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1093\/rheumatology\/keq035","article-title":"Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort","volume":"49","author":"Koduri","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.intimp.2020.106748_b0015","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1164\/rccm.201004-0622OC","article-title":"Rheumatoid arthritis-interstitial lung disease-associated mortality","volume":"183","author":"Olson","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.intimp.2020.106748_b0020","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/art.20878","article-title":"Cardiovascular death in rheumatoid arthritis: a population-based study","volume":"52","author":"Maradit-Kremers","year":"2005","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.intimp.2020.106748_b0025","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/art.27405","article-title":"Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study","volume":"62","author":"Bongartz","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2020.106748_b9010","doi-asserted-by":"crossref","DOI":"10.2217\/bmm-2019-0545","article-title":"Krebs von den Lungen-6 as biomarker for disease severity assessment in interstitial lung disease: a comprehensive review","author":"d\u2019Alessandro","year":"2020","journal-title":"Biomarkers Med."},{"issue":"5","key":"10.1016\/j.intimp.2020.106748_b0030","first-page":"1164","article-title":"KL-6 as a novel serum marker for interstitial pneumonia associated with collagen diseases","volume":"27","author":"Nakajima","year":"2000","journal-title":"J. Rheumatol."},{"issue":"Pt 1","key":"10.1016\/j.intimp.2020.106748_b0035","first-page":"1","article-title":"Principles of interleukin (IL)-6-type cytokine signalling and its regulation","volume":"374","author":"Heinrich","year":"2003","journal-title":"Biochem. J."},{"issue":"11","key":"10.1016\/j.intimp.2020.106748_b0040","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/ncprheum0338","article-title":"Interleukin 6: from bench to bedside","volume":"2","author":"Nishimoto","year":"2006","journal-title":"Nat. Clin. Pract. Rheumatol."},{"issue":"6","key":"10.1016\/j.intimp.2020.106748_b0045","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/art.1780310614","article-title":"Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides","volume":"31","author":"Houssiau","year":"1988","journal-title":"Arthritis Rheum."},{"issue":"7","key":"10.1016\/j.intimp.2020.106748_b0050","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/acr.22513","article-title":"Evaluation of serum interleukin-6 level as a surrogate marker of synovial inflammation and as a factor of structural progression in early rheumatoid arthritis: results from a French national multicenter cohort","volume":"67","author":"Baillet","year":"2015","journal-title":"Arthritis Care Res. (Hoboken)."},{"issue":"8","key":"10.1016\/j.intimp.2020.106748_b0055","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-003199","article-title":"IL-6 pathway-driven investigation of response to IL-6 receptor inhibition in rheumatoid arthritis","volume":"3","author":"Wang","year":"2013","journal-title":"BMJ Open."},{"key":"10.1016\/j.intimp.2020.106748_b9000","article-title":"Bronchoalveolar lavage proteomic analysis in pulmonary fibrosis associated with systemic sclerosis: S100A6 and 14-3-3\u03b5 as potential biomarkers","author":"Landi","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.intimp.2020.106748_b0060","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.intimp.2020.106748_b0065","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1164\/rccm.201710-1981ST","article-title":"Recommendations for a standardized pulmonary function report. An official American thoracic society technical statement","volume":"196","author":"Culver","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.intimp.2020.106748_b0070","doi-asserted-by":"crossref","DOI":"10.1007\/s11739-020-02281-8","article-title":"Bronchoalveolar lavage and serum KL-6 concentrations in chronic hypersensitivity pneumonitis: correlations with radiological and immunological features","author":"Lanzarone","year":"2020","journal-title":"Int. Emerg. Med."},{"issue":"2","key":"10.1016\/j.intimp.2020.106748_b0075","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10238-020-00613-8","article-title":"Correction to: BAL biomarkers' panel for differential diagnosis of interstitial lung diseases","volume":"20","author":"d'Alessandro","year":"2020","journal-title":"Clin. Exp. Med."},{"issue":"2","key":"10.1016\/j.intimp.2020.106748_b0080","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s10238-020-00608-5","article-title":"BAL biomarkers' panel for differential diagnosis of interstitial lung diseases","volume":"20","author":"d'Alessandro","year":"2020","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.intimp.2020.106748_b0085","article-title":"Serum KL-6 levels in pulmonary langerhans' cell histiocytosis","volume":"20","author":"d'Alessandro","year":"2020","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.intimp.2020.106748_b0090","doi-asserted-by":"crossref","DOI":"10.1515\/cclm-2019-1145","article-title":"Interleukin-6 chemiluminescent immunoassay on Lumipulse G600 II: analytical evaluation and comparison with three other laboratory analyzers","author":"Glady","year":"2020","journal-title":"Clin. Chem. Lab. Med."},{"issue":"3","key":"10.1016\/j.intimp.2020.106748_b0095","doi-asserted-by":"crossref","first-page":"156","DOI":"10.5694\/j.1326-5377.1997.tb140053.x","article-title":"Rheumatoid arthritis","volume":"166","author":"Ahern","year":"1997","journal-title":"Med. J. Aust."},{"issue":"4","key":"10.1016\/j.intimp.2020.106748_b0100","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"issue":"5","key":"10.1016\/j.intimp.2020.106748_b0105","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3899\/jrheum.130683","article-title":"Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies","volume":"41","author":"Wollenhaupt","year":"2014","journal-title":"J. Rheumatol."},{"issue":"7","key":"10.1016\/j.intimp.2020.106748_b0110","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1136\/annrheumdis-2017-212461","article-title":"Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies","volume":"77","author":"Taylor","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2020.106748_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ccm.2011.12.002","article-title":"Approach to the diagnosis of interstitial lung disease","volume":"33","author":"Behr","year":"2012","journal-title":"Clin. Chest Med."},{"issue":"6","key":"10.1016\/j.intimp.2020.106748_b0120","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0033-8389(05)70334-1","article-title":"CT signs and patterns of lung disease","volume":"39","author":"Collins","year":"2001","journal-title":"Radiol. Clin. North Am."},{"key":"10.1016\/j.intimp.2020.106748_b0125","article-title":"BAL biomarkers' panel for differential diagnosis of interstitial lung diseases","author":"d'Alessandro","year":"2020","journal-title":"Clin. Exp. Med"},{"issue":"3","key":"10.1016\/j.intimp.2020.106748_b0130","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s10067-015-3167-8","article-title":"Association of serum KL-6 levels with interstitial lung disease in patients with connective tissue disease: a cross-sectional study","volume":"35","author":"Oguz","year":"2016","journal-title":"Clin. Rheumatol."},{"issue":"3","key":"10.1016\/j.intimp.2020.106748_b0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229997","article-title":"Prognostic role of blood KL-6 in rheumatoid arthritis-associated interstitial lung disease","volume":"15","author":"Kim","year":"2020","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.intimp.2020.106748_b0140","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13075-019-1835-9","article-title":"Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease","volume":"21","author":"Lee","year":"2019","journal-title":"Arthritis Res. Ther."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920313771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920313771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:58:03Z","timestamp":1769029083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576920313771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":31,"alternative-id":["S1567576920313771"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2020.106748","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of baricitinib in treating rheumatoid arthritis: Modulatory effects on fibrotic and inflammatory biomarkers in a real-life setting","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2020.106748","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106748"}}